Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA235-0001  |   NCT06419634

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • 5
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    1. Detectable levels of cluster of differentiation 33 (CD33) expression.
      1. Failed alternative therapies with established benefit.
        1. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate organ function.

          Exclusion Criteria

          Exclusion Criteria Icon
          :
          • Acute Promyelocytic Leukemia.
            1. Clinically active central nervous system leukemia.
              1. Active malignant solid tumor.
                1. Pregnant or breastfeeding.
                  1. Other protocol-defined inclusion/exclusion criteria apply.
                    Additional Information *

                    Treatment Options

                    Study Arms

                    ASSIGNED INTERVENTION

                    Study Arms

                    Experimental: Part 1: Dose Escalation BMS-986497

                    ASSIGNED INTERVENTION
                    • Drug: BMS-986497

                    Study Arms

                    Experimental: Part 2: Dose Expansion BMS-986497

                    ASSIGNED INTERVENTION
                    • Drug: BMS-986497
                    Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                    Check Your Eligibility
                    Answer some questions about Your health to see if you may match to this trial
                    Match to a Trial
                    If you are a match, click on the study to see the list of study site locations
                    Select a Study Site Location
                    Select a study site location that is convenient for you
                    Register
                    Provide your contact details for the study site to connect with you.

                    Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you